论文部分内容阅读
目前抗EGFR治疗只应用于KRAS野生型转移性结直肠患者,然在这些患者的获益率只有不到40%。因而寻找更多更精确的生物标志物用于筛选出最适宜的治疗患者显得尤为迫切。为此,多中心协作开展了一项研究,该研究目的是筛选出能预测KRAS野生型转移性结直肠患者抗EGFR治疗疗效的miRNAs。该研究分析了87例mCRC患者miRNA表达谱,这些患者
Currently, anti-EGFR therapy is only used in patients with KRAS wild-type metastatic colorectal cancer, although the benefit rate of these patients is less than 40%. Therefore, looking for more and more accurate biomarkers for screening the most suitable treatment of patients is particularly urgent. To this end, the Multicentre Collaboration conducted a study to screen for miRNAs that predict the efficacy of anti-EGFR therapy in patients with KRAS wild-type metastatic colorectal cancer. The study analyzed miRNA expression profiles in 87 patients with mCRC and these patients